Matthew E. Korenberg - 15 Feb 2022 Form 4 Insider Report for LIGAND PHARMACEUTICALS INC (LGND)

Role
EVP,Finance & Strategy and CFO
Signature
By: Charles S. Berkman For: Matthew E. Korenberg
Issuer symbol
LGND
Transactions as of
15 Feb 2022
Net transactions value
-$421,378
Form type
4
Filing time
16 Feb 2022, 19:23:22 UTC
Previous filing
28 Jan 2022
Next filing
09 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LGND Common Stock Tax liability $112,054 -906 -1.9% $123.68 46,807 15 Feb 2022 Direct F1
transaction LGND Common Stock Tax liability $119,846 -969 -2.1% $123.68 45,838 15 Feb 2022 Direct F2
transaction LGND Common Stock Tax liability $189,478 -1,532 -3.3% $123.68 44,306 15 Feb 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/11/2019.
F2 Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/13/2020.
F3 Represents shares withheld to satisfy tax withholding obligations upon the vesting of previously reported restricted stock units that were granted on 02/03/2021.